Update on Effectiveness and Impact of PCV13 use among U.S. Children


Matthew R. Moore, MD, MPH
Captain, USPHS
Centers for Disease Control & Prevention
26 February 2014




Methods

- CDC monitors invasive pneumococcal disease (IPD) using active, population-based surveillance conducted in 10 areas around U.S. (Active Bacterial Core surveillance, ABCs)
- Evaluated rates of IPD over time
- Focused on 5 PCV13 types not affected by PCV7
 - PCV7 includes serotypes 4, 6B, 9V, 14, 18C, 19F, 23F
 - Serotype 6B antigen of PCV7 provides cross-protection against serotype 6A
 - Serotype 6A is included in PCV13
- Also evaluated for evidence of serotype replacement
- Individual-level vaccine effectiveness (VE) evaluated among children 2-59 months old using case-control method


Annual Trends in IPD among Children <5 years old, 2006-13




Annual Trends in IPD among Adults 18-49 years old, 2006-13



Annual Trends in IPD among Adults 50-64 years old, 2006-13



Annual Trends in IPD among Adults >65 years old, 2006-13



Percent Change in PCV5-type IPD, Comparing Observed Cases to Cases Expected in Absence of PCV13, by age

| Age | Percent Change in Rate (95%IE) | | |
|-----------------|--------------------------------|----------------|----------------|
| group, years | 2010-11 | 2011-12 | 2012-13 |
| <5 | -66 (-61, -70) | -88 (-86, -89) | -93 (-91, -94) |
| 5-17 | -35 (-21, -45) | -59 (-48, -66) | -75 (-67, -80) |
| 18-49 | -33 (-26, -38) | -64 (-60, -68) | -72 (-69, -75) |
| 50-64 | -23 (-18, -28) | -54 (-50, -57) | -62 (-59, -65) |
| <u>></u> 65 | -23 (-13, -31) | -46 (-39, -52) | -58 (-52, -64) |

Continued reductions in vaccine-type IPD in all age groups during first 3 years after PCV13 introduction.

Percent Change in Non-PCV13-type IPD, Comparing Observed Cases to Cases Expected in Absence of PCV13, by age

| Age | Percent Change in Rate (95%IE) | | |
|-----------------|--------------------------------|--------------|--------------|
| group, years | 2010-11 | 2011-12 | 2012-13 |
| <5 | -4 (-16, 12) | 7 (-9, 31) | -2 (-19, 27) |
| 5-17 | -11 (-31, 25) | 32 (-2, 110) | -2 (-32, 80) |
| 18-49 | 3 (-6, 15) | -10 (-20, 4) | 13 (-2, 34) |
| 50-64 | 8 (0, 18) | 0 (-9, 12) | 26 (13, 44) |
| <u>></u> 65 | 1 (-6, 10) | -7 (-15, 3) | 7 (-4, 20) |


Possible early evidence of serotype replacement among adults 50-64 years old.

Percent Change in All IPD, Comparing Observed Cases to Cases Expected in Absence of PCV13, by age

| Age | Percent Change in Rate (95%IE) | | |
|-----------------|--------------------------------|----------------|----------------|
| group, years | 2010-11 | 2011-12 | 2012-13 |
| <5 | -45 (-40, -50) | -58 (-53, -63) | -64 (-59, -68) |
| 5-17 | -33 (-18, -45) | -36 (-16, -49) | -53 (-35, -64) |
| 18-49 | -12 (-5, -20) | -37 (-30, -43) | -32 (-22, -40) |
| 50-64 | -8 (-2, -14) | -28 (-22, -33) | -18 (-10, -26) |
| <u>></u> 65 | -6 (-14, 3) | -19 (-9, -27) | -12 (-22, 1) |

Significant reductions in overall IPD in all age groups through first 3 years of PCV13 use among children.

National Cases & Deaths of IPD Prevented following PCV13 Introduction, July 2010 - June 2013



Case-Control Study of PCV13 Effectiveness: Preliminary Estimates

- Cases: 2-59 month-old children with IPD residing in 10 ABCs areas, New York City, Los Angeles County, Utah
- May 2010 September 2013
 - Enrolled 760 cases
 - 224 (29%) had PCV13-type IPD
 - 209 (93%) were caused by serotypes 19A, 7F, and 3
 - Enrolled 3,519 controls (mean 3 controls per case)
 - Receipt of ≥1 dose among controls increased from 38% in June-November 2010 to 96% in May-September 2013

| Outcome | VE <u>≥</u> 1 dose, % | 95% CI |
|----------------|-----------------------|--------|
| All IPD | 59 | 45-70 |
| PCV13-type IPD | 89 | 79-94 |
| Serotype 19A | 90 | 76-96 |
| Serotype 7F | 100 | 100 |
| Serotype 3 | 76 | 13-93 |

Conclusions

- Reductions in IPD caused by additional serotypes in PCV13 among all age groups, indicative of direct and indirect effects
- Early evidence of increases in non-PCV13 serotypes, possibly suggestive of serotype replacement
- Preliminary evidence of serotype-specific effectiveness for 3 most common PCV13 serotypes; additional analysis pending

California EIP

- Art Reingold
- Duc Vugia
- James Watt
- Gretchen Rothrock
- Pam Daily
- Joelle Nadle
- Mirasol Apostol
- Katie Wymore
- Lauren Pasutti
- Erin Garcia
- Erin Parker
- Mariah Hamilton
- Nick Czap

Los Angeles County DPH

- Laurene Mascola
- Ramon Guevara
- Tasneem Motala

Colorado EIP

- Ken Gershman
- Deborah Aragon
- Jen Sadlowski
- Ben White
- Wendy Bamberg

Connecticut EIP

- Matt Carter
- Terry Rabatsky-Ehr
- Heather Altier
- Susan Petit
- Carmen Marguez
- Michelle Wilson

Georgia EIP

- Monica Farley
- Wendy Baughman
- Janine Ladson
- Amy Holst
- Stepy Thomas
- Sasha Harb
- Suzanne Segler
- Lauren Lorenztson
- Matt Crist
- Jessica Reno
- Lewis Perry
- Calista Schenck
- Melissa Tobin D'Angelo

Acknowledgments

Maryland EIP

- Lee Harrison
- David Blythe
- Patricia Ryan
- Rosemary Hollick
- Joanne Benton
- Terresa Carter
- Kim Holmes
- Kathleen Shutt
- Lindsay Saxman
- Andrea Riner
- Mary Messenger
- Helen Yoon
- Carolyn Kreiner

Minnesota EIP

- Richard Danila
- Ruth Lynfield
- Catherine Lexau
- Lori Triden
- Brenda Jewell
- Corinne Holtzmann
- Christine Lees
- Billie Juni

New Mexico EIP

- Joan Baumbach
- Megin Nichols
-
- Joseph Bareta
- Sarah Khalnlian
- Robert Mansmann
- Lisa Butler
- Kathy Angeles
- Gabriela Keener

Thank you!

New York EIP

- Gus Birkhead
- Nancy Bennett
- Deb Blog
- Shelley Zansky
- Nancy Spina
- Glenda Smith
- Jillian Karr
- Suzanne Solghan
- Kari Burzlaff
- Salvatore Currenti
- Greg Giambrone
- Nellie Dumas
- Kimberlee Musser
- Ghinwa Dumyati
- Anita Gellert
- Gary Hollick

Oregon EIP

- Paul Cieslak
- Ann Thomas
- Heather Jamieson
- Treather JamlesonTasha Poissant

Tennessee EIP

- William Schaffner
- Mary Lou Lindegren
- Tim Jones
- Brenda Barnes
- Mellnda Eady
- Terri McMinn
- Katie Gore
- Lynne Fenner
- , , , , , ,
- Sandra Gray
- Lura McKnightWendi Welch
- Karen Leib
- Henrietta Hardin

New York City DHMH

- Jennifer Rosen
- Sarah Borderud
- Andrea Farnham

Utah Dept. of Health

- Kristina Russell
- Melissa Stevens

CDC ABCs Team

- Gayle Fischer Langley
- Chris Van Beneden
- Emily Weston
- Londell McGlone
- Carolyn Wright
- Karrie-Ann Toews
- Ruth Link-Gelles
- Ryan Gierke
- Tamara Pilishvili
- Cyndy Whitney
- Matt Moore
- Stephanie Schrag
- Nancy Messonnier
- Amanda Cohn
- Elizabeth Briere
- Jessica MacNeil
- Tami SkoffAmanda Faulkner
- Elizabeth Zell
- Tom Taylor
- Melissa Lewis
-
- Tracy Pondo
- Scott Fridkin
 Fernanda Lessa
- Sandie Bulens
- Shierley Zhang
- Ruth Belflower
- Bernie Beall
- Lesley McGee
- Logan SherwoodDee Jackson
- Leonard Mayer
- Jennie Thomas
- Ravdel Mair
- 13
- Greg Fosheim Valerie Schoonover